10b-Hydroxy-4-phenyl-2,3-dihydrobenzo[h][1,4]benzoxazin-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 10b-Hydroxy-4-phenyl-2,3-dihydrobenzo[h][1,4]benzoxazin-6-one
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.3
• InChiKey: SMUHSRARSBTTHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Compounds for modulating integrin CD11B/CD18
  申请人：The General Hospital Corporation

  公开号：US10408820B2

  公开（公告）日：2019-09-10

  The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

  该申请描述了一种用于鉴定整合素 CD11b/CD18 小分子调节剂和能够调节该受体活性的小分子的检测方法。在某些实施方案中，此类化合物可用于治疗选自炎症、免疫相关疾病、癌症、缺血再灌注损伤、中风、与血管损伤相关的新内膜增厚、牛皮癣、新生儿阻塞性肾病和心血管疾病的疾病或病症、或在其他实施方案中，用于治疗选自免疫缺陷、获得性免疫缺陷综合征（艾滋病）、髓过氧化物酶缺乏、Wiskott-Aldrich 综合征、慢性肉芽肿病、高 IgM 综合征、白细胞粘附缺陷、Chediak-Higashi 综合征和严重联合免疫缺陷的疾病或病症。
• Compounds for modulating integrin CD11b/CD18
  申请人：Gupta Vineet

  公开号：US20100056503A1

  公开（公告）日：2010-03-04

  The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
• GALACTOKINASE INHIBITORS
  申请人：Lai Kent

  公开号：US20110251236A1

  公开（公告）日：2011-10-13

  Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.
• COMPOUNDS FOR MODULATING INTEGRIN CDIIb/CDI8
  申请人：Gupta Vineet

  公开号：US20130045967A1

  公开（公告）日：2013-02-21

  The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
• Compounds for Modulating Integrin CD11B/CD18
  申请人：The General Hospital Corporation

  公开号：US20140303026A1

  公开（公告）日：2014-10-09

  The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.